Search | Clinical Trials Finder

Conditions: Healthy Volunteers
Interventions: Esketamine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Cartilage Disease
Interventions: Meniscus repair for red/white tears without PRP, Meniscus repair with PRP; Procedure
Lead sponsor: Sue Barber-Westin; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: White Spot Lesion, Orthodontic Treatment, Decalcification; Teeth
Interventions: Clinpro™ 5000, Clinpro™ Tooth Crème, MI-Paste Plus; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 12 Years to 60 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Patient Satisfaction
Interventions: non White coat; Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 178 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Brain Neoplasms
Interventions: Whole Brain Irradiation, Partial Brain Irradiation, Neuropsychological Testing, Quality of Life Questionnaire, Magnetic Resonance Imaging (MRI) Assessments; Radiation · Behavioral · Device
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Essential Tremor, Parkinson's Disease
Interventions: DaTscan™ - Non-Caucasian Participants, DaTscan™ - Caucasian Participants; Other
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Marlborough, Massachusetts

Conditions: Healthy
Interventions: single dose NJ-39758979/ matching placebo, multi-dose JNJ-39758979 /matching placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Cypress, California

Conditions: Alcoholism
Interventions: Placebo Oral Tablet, Naltrexone; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 64 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: AZD1305, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 45 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Healthy
Interventions: TG-2349 as the original formulation, TG-2349 as a new capsule formulation; Drug
Lead sponsor: TaiGen Biotechnology Co., Ltd.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Colitis, Ulcerative, Cholangitis, Sclerosing
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Osteoporosis
Interventions: Low Na diet (1.3 g/d), High sodium diet (3.8 g/d); Other
Lead sponsor: Purdue University; Other
Eligibility: 11 Years to 15 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Traumatic Brain Injury, TBI, Sleep
Interventions: Bright White Light (BWL), Red Light (RL); Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 70 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Attention Deficit Disorder With Hyperactivity, Healthy
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 6 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hodgkins Lymphoma, Non-hodgkins Lymphoma
Interventions: Not listed
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 6 Years to 18 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
Interventions: Rituximab, N-803; Biological
Lead sponsor: Altor BioScience; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 4
States / cities: Minneapolis, Minnesota • St Louis, Missouri • Columbus, Ohio + 1 more

Conditions: Hematologic Malignancy
Interventions: AM4113-N5UT Dino-Lite; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bacterial Vaginoses
Interventions: Secnidazole; Drug
Lead sponsor: Lupin Research Inc; Industry
Eligibility: 12 Years to 17 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Long Beach, California • Hialeah, Florida • Miami Lakes, Florida + 6 more

Conditions: Healthy Volunteers
Interventions: Risankizumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Cypress, California

Conditions: Prematurity, Very Preterm Maturity of Infant
Interventions: SNOO Smart Sleeper, Traditional bassinet; Device
Lead sponsor: Columbia University; Other
Eligibility: 1 Week to 12 Weeks
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Open Angle Glaucoma (POAG)
Interventions: Direct Selective Laser Trabeculoplasty; Device
Lead sponsor: Select Eye Care; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Elkridge, Maryland

Conditions: Parkinson Disease
Interventions: BIA 9-1067, Placebo; Drug
Lead sponsor: Bial - Portela C S.A.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Healthy
Interventions: LY3471851, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 20 Years to 64 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cypress, California

Conditions: Dermatitis, Atopic
Interventions: GSK1070806, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Cypress, California • Las Vegas, Nevada

Search by objective public record fields.

A Study to Assess the Pharmacokinetics of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Volunteers

Assessment of Outcome of Meniscus Repair With or Without Platelet Rich Plasma

Comparison of Three Toothpastes for the Prevention and Reduction of White Spot Lesions

Physician Attire and Appreciation of Physician Communication in Postpartum Women

MRI Study of Radiation-Induced Damage to White Matter and Blood-Brain-Barrier

Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)

Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent

Understanding Treatment Response With Naltrexone Among White Alcoholics

AZD1305 Single and Multiple Ascending Dose Study in Healthy Japanese and Caucasian Subjects

Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers

Compare Conventional Colonosocpy to Endoscopic AFI, NBI for Dysplasia Detection for Ulcerative Colitis & Cholangitis

Effect of Sodium Intake on Calcium Retention in Girls

TWILIGHT Study: Effect of Light Exposure During Acute Rehabilitation on Sleep After TBI

Brain Imaging in Children With AD/HD

Brown Fat Activity and White Fat Accumulation

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Non Invasive Optical Imaging of WBC Count

Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV

A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab

Sleep in SNOO Smart Sleeper Bassinet in Preterm Infants

Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma

Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

A Study of LY3471851 in Healthy Participants

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive